Showing results (1-10 of 196) with videos related to
Sort By:
Pageof 20
Endocrinology and Metabolism Clinics of North America|February 26, 2011
Standard imaging techniques for neuroendocrine tumorsDavid L Bushnell, Richard P BaumSurgical Oncology Clinics of North America|March 11, 2020
Overview and Current Status of Peptide Receptor Radionuclide TherapyDavid L Bushnell, Kellie L BodekerDalton Transactions (Cambridge, England : 2003)|March 30, 2011
Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICSFrank Rösch, Richard P BaumPET Clinics|July 18, 2014
Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapyMatthias Blaickner, Richard P BaumEuropean Journal of Nuclear Medicine and Molecular Imaging|December 24, 2008
Multimodality image registration with software: state-of-the-artPiotr J Slomka, Richard P BaumPET Clinics|July 18, 2014
Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapyHarshad R Kulkarni, Richard P BaumTheranostics|July 7, 2012
THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka ExperienceRichard P Baum, Harshad R KulkarniClinical Nuclear Medicine|November 12, 2013
Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATEAurora Sainz-Esteban, Richard P BaumPET Clinics|July 18, 2014
Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CTHarshad R Kulkarni, Richard P BaumEuropean Journal of Nuclear Medicine and Molecular Imaging|May 8, 2025
Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in GermanyCarolin Brinkmann, Richard P Baum, Tom StargardtPageof 20